NCT01044433 · OUTCOME

Overall Survival

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck · Source last updated 2020-03-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: Months
Interval / dispersion: 90% Confidence Interval
Time frame: 5 years

Groups in this outcome

Lapatinib Ditosylate and Capecitabine

Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14. lapatinib ditosylate: Given orally capecitabine: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Lapatinib Ditosylate and Capecitabine	44

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 90% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Lapatinib Ditosylate and Capecitabine	10.7	Not reported	8.7	12.9	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
8.7
upper Limit
12.9
value
10.7

denoms

counts
group Id
OG000
value
44
units
Participants

dispersion Type

90% Confidence Interval

groups

description
Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14. lapatinib ditosylate: Given orally capecitabine: Given orally
id
OG000
title
Lapatinib Ditosylate and Capecitabine

param Type

MEAN

reporting Status

POSTED

time Frame

5 years

title

Overall Survival

type

PRIMARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice